Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXTGEN-TIL in Advanced Epithelial and ICB-Resistant Solid Tumors
NCT05141474Phase 1Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2021
- Primary completion
- Jan 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NEXTGEN-TIL in Epithelial tumor and solid tumor, sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Incidence of Adverse Events (AE) at 6 months, Incidence of Serious Adverse Events (SAE) at 6 months and 6 more. Started Oct 2021; status: recruiting.
02
Drugs
NEXTGEN-TIL
03
Conditions
Epithelial tumorsolid tumor
Beyond the preview
Go deeper on NCT05141474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141474.